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Nitrofurantoin has been documented as a cause of acute, sub-acute, and chronic pulmonary injury. This is
a case of an 82 year-old female who presented with multiple episodes of respiratory symptoms due to
recurrent pleural effusions after beginning nitrofurantoin therapy for urinary tract infection prophylaxis.
Due to the rarity of pleural effusion as an adverse reaction to nitrofurantoin, the diagnosis was over-
looked at ﬁrst. This led to the patient undergoing multiple invasive procedures and accruing unnecessary
healthcare cost before the diagnosis was made. This case demonstrates the need for physicians to remain
mindful of rare adverse reactions from medications and maintain a high index of clinical suspicion with
any patient presenting with a respiratory complaint while taking nitrofurantoin.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Nitrofurantoin has long been a staple for the treatment of uri-
nary tract infections, either as a seven day course or as daily pro-
phylaxis but recent guidelines has listed its use as potential ﬁrst-
line treatment of uncomplicated UTI. It has been an excellent
alternative treatment for those with sulfa allergies, unable to
tolerate trimethoprim-sulfamethoxazole. But, nitrofurantoin
adverse events have been well documented throughout the liter-
ature for years. Most commonly nitrofurantoin causes gastroin-
testinal upset which includes nausea, vomiting, and diarrhea
among others. Although rare, pulmonary adverse reactions have
been the focus of many published works discussing the acute,
subacute, and chronic effects of nitrofurantoin on the lungs [1,2]. A
PubMed review of clinical cases over the last ten years found dis-
cussions of reactions including pulmonary ﬁbrosis, interstitial
pneumonitis, and hypersensitivity pneumonia [3,4]. When
searching for nitrofurantoin-induced pleural disease, no cases have
been documented since 2004 [5]. The objective of this report is to
describe a rare but documented hypersensitivity reaction to
nitrofurantoin in order to assist clinicians in identifying sequential
relationships between symptoms and drug treatment to diagnoseapp Rd, Cottondale, FL 32431,
Ltd. This is an open access article uadverse drug reactions in their patients sooner rather than later.2. Case report
An 82 year old female presented to her primary care physician
with symptoms of dyspnea and right-sided chest pain which had
been ongoing for one week. The patient had been previously in
good health prior to her presentation. Physical exam revealed
decreased breath sounds at the right lung base with decreased
fremitus but was negative for any other physical exam ﬁnding
including a cutaneous rash, which has been linked to
nitrofurantoin-induced Lupus. Her medical history included
chronic urinary tract infections for which in the last month she had
been placed on nitrofurantoin 100 mg daily for prophylaxis. Labo-
ratory results from the initial presentation showed that the Anti-
nuclear Antibody test (ANA) was negative which made a Lupus
reaction less likely. An Erythrocyte Sedimentation Rate was
checked but was within normal limits (32). Her ECG was normal
and a transthoracic echocardiogram prior to her initial visit
revealed normal heart structure and functionwith a left ventricular
ejection fraction estimated at sixty percent. Therefore, cardiac
cause was thought to be less likely and the patient was sent for a
chest radiograph and thoracentesis with pleural ﬂuid analysis for
diagnosis. The radiograph showed signiﬁcant right-sided pleural
effusion. At that time she underwent a thoracentesis which
removed 600 cc of clear ﬂuid but ultimately did not ﬁnd a cause fornder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Image 1. CT Scan.
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tient was sent home with total resolution of her symptoms and a
diagnosis of idiopathic pleural effusion. She was given an
appointment with a pulmonologist, who also agreed in the diag-
nosis of idiopathic pleural effusion.
The patient remained in good health without recurrence of
symptoms for one month. After one month, once again she began
experiencing dyspnea and pain localized to the right chest and
presented to her primary care physician. Physical exam yet again
revealed decreased breath sounds at the right lung base with
decreased fremitus. The patient was sent for a CT scan performed
without contrast which revealed a mild to moderate right pleural
effusion (Image 1).
A thoracentesis was then performed, removing another 600 cc
of clear yellow tinted ﬂuid. Still no etiology was identiﬁed. After the
thoracentesis the patient yet again experienced total resolution of
her dyspnea and chest pain.
Within the next two weeks, the patient experienced another
urinary tract infection prompting her to visit the Urologist who had
prescribed the nitrofurantoin. During her visit, her medication was
switched to trimethoprim-sulfamethoxazole in order to treat this
breakthrough UTI. Over the next three months, the patient was not
prescribed nitrofurantoin. She did not develop any pulmonary
symptoms throughout this time. At a follow up visit to her primary
care physician during this three month window she was found to
be asymptomatic and in good health without any signs or symp-
toms of a recurrent pleural effusion. After this time the patient
began experiencing symptoms of a urinary tract infection and she
was placed back on chronic nitrofurantoin at the same dosage for
prophylactic treatment.
It took three weeks after restarting the nitrofurantoin therapy
for the patient to begin experiencing similar symptoms of dys-
pnea and chest pain. She presented to her primary care physician
with the same physical exam ﬁndings as was found previously.
But at this visit, both the patient and her provider now had a
higher degree of suspicion for a drug induced pleural effusion
once the patient had recalled the three month asymptomatic
period at which time the only change was the medication taken
for UTI treatment. The recurrent episodes of pleural effusion at
the same time the patient began taking nitrofurantoin and the
resolution of symptoms once the medication was discontinued
both met the Naranjo criteria of medication induced adverse re-
actions. It was at this time that the patient and her primary
physician decided to discontinue the nitrofurantoin. A therapeutic
thoracentesis was performed and withdrew 700 cc of clear
pleural ﬂuid. Fluid analysis still could not deﬁne a speciﬁc etiology
and the patient was sent home asymptomatic with plans for close
follow up.
One month following, the patient presented to her primary care
physician for her follow up appointment. She continued to be
asymptomatic, without any difﬁculty in breathing or chest pain.
The patient also remained off nitrofurantoin and was now taking a
different medication for urinary tract infections. A chest radiograph
conﬁrmed that the patient had total resolution of the pleuralTable 1
Pleural ﬂuid chemistry.
Pleural ﬂuid analysis
Red Blood Cells 399 Segmented Neutrophils 17
White Blood Cells 1350 Glucose 127
Eosinophils 9 LDH 167
Lymphocytes 39 Protein 4
Monocytes 35 pH 7.51effusion. A transthoracic echocardiogram was performed and
remained virtually unchanged from her previous study (TTE results
found in Image 2). The patient was also referred to a pulmonologist
at a tertiary care center who, after examining the patient and
studying her records, agreed that the recurrent pleural effusionwas
indeed nitrofurantoin induced. After discontinuation of the medi-
cation the patient remained asymptomatic at all of her subsequent
visits to her primary care physician.3. Discussion
This case demonstrates a rarely documented adverse reaction
to nitrofurantoin. Because pleural effusion is not often included as
a potential pulmonary toxicity caused by nitrofurantoin therapy it
can be easy for even the most experienced clinicians to neglect to
tie the medication to the diagnosis. This case is evidence that an
unexplained pleural disease, in the presence of nitrofurantoin
use, should raise suspicion of a drug induced mechanism of
injury.
This case scored highly on the Naranjo Scale indicating a high
probability that the injurywas a drug induced adverse reaction. The
Naranjo Scale aids in making a diagnosis of drug induced adverse
reaction when used in conjunction with clinical judgement. It is a
useful tool in cases such as this when the mechanism of injury is
rare and seemingly unexplained.
The case exhibits the need for physicians to remain mindful of
rare adverse reactions from medications. This patient underwent
multiple invasive procedures and accrued substantial healthcare
cost all stemming from a reaction that resolved upon the discon-
tinuation of a single medication. As this case proves, elderly pa-
tients are at an even higher risk of adverse reactions and drug
interactions. The 2015 AGS Beers List recommended against the use
of nitrofurantoin in the elderly. In those with renal impairment, the
drug reaches higher systemic levels, increasing the risk for toxic-
ities [6]. Polypharmacy is also a rather important issue in this age
group which can further cloud the clinical picture. All of these
factors provide further evidence for clinicians to perform a com-
plete medication review when their patients present with unex-
plained symptoms, especially the elderly population. In doing so,
the potential risk for harmwill be lowered and patients will be less
often subjected to invasive procedures which carry inherent risk of
complication and increased cost.
Image 2. TTE Results.
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